Clozapine Monitoring in Clinical Practice: Beyond the Mandatory Requirement

키워드

참고문헌 (66)

1. Schulte P, "What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatmentrefractory schizophrenia", Clin Pharmacokinet, 42, pp.607~618 (2003)
2. Meltzer HY, "Clozapine: balancing safety with superior antipsychotic efficacy", Clin Schizophr Relat Psychoses, 6, pp.134~144 (2012)
3. Xiang YT, "Clozapine use in schizophrenia: findings of the Research on Asia Psychotropic Prescription (REAP) studies from 2001 to 2009", Aust N Z J Psychiatry, 45, pp.968~975 (2011)
4. Tian-Mei Si, "Use of Clozapine for the Treatment of Schizophrenia: Findings of the 2006 Research on the China Psychotropic Prescription Studies", Clinical Psychopharmacology and Neuroscience, 10(2), pp.99~104 (2012), 대한정신약물학회[DOI]
5. Forrester T, "Increasing clozapine dispensing trends in Queensland, Australia 2004-2013", Pharmacopsychiatry, 48, pp.164~169 (2015)
6. Mortimer AM, "Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world", Clin Schizophr Relat Psychoses, 4, pp.49~55 (2010)
7. Nielsen J, "Psychiatrists'attitude towards and knowledge of clozapine treatment", J Psychopharmacol, 24, pp.965~971 (2010)
8. Cohen D, "Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy", J Clin Psychiatry, 73, pp.1307~1312 (2012)
9. Taylor DM, "Reasons for discontinuing clozapine: matched, case-control comparison with risperidone long-acting injection", Br J Psychiatry, 194, pp.165~167 (2009)
10. Nielsen J, "Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?", J Clin Psychiatry, 74, pp.603~613 (2013)
11. Alvir JM, "Clozapine-induced agranulocytosis. Incidence and risk factors in the United States", N Engl J Med, 329, pp.162~167 (1993)
12. Kang BJ, "Long-term patient monitoring for clozapine-induced agranulocytosis and neutropenia in Korea: when is it safe to discontinue CPMS?", Hum Psychopharmacol, 21, pp.387~391 (2006)
13. Schulte P, "Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring", Ann Pharmacother, 40, pp.683~688 (2006)
14. Patel NC, "Sudden late onset of clozapine-induced agranulocytosis", Ann Pharmacother, 36, pp.1012~1015 (2002)
15. Lahdelma L, "Clozapine-induced agranulocytosis in Finland, 1982-2007: long-term monitoring of patients is still warranted", J Clin Psychiatry, 73, pp.837~842 (2012)
16. Aakanksha Singh, "Late Onset Agranulocytosis with Clozapine Associated with HLA DR4 Responding to Treatment with Granulocyte Colony-stimulating Factor: A Case Report and Review of Literature", Clinical Psychopharmacology and Neuroscience, 14(2), pp.212~217 (2016), 대한정신약물학회
17. Mackin P, "Cardiac side effects of psychiatric drugs", Hum Psychopharmacol, 23(Suppl 1), pp.3~14 (2008)
18. Merrill DB, "Adverse cardiac effects associated with clozapine", J Clin Psychopharmacol, 25, pp.32~41 (2005)
19. Hägg S, "Myocarditis related to clozapine treatment", J Clin Psychopharmacol, 21, pp.382~388 (2001)
20. Ronaldson KJ, "Clinical course and analysis of ten fatal cases of clozapine-induced myocarditis and comparison with 66surviving cases", Schizophr Res, 128, pp.161~165 (2011)
21. Chung SJ, "Autonomic nervous system related adverse effects developed during clozapine treatment", Korean J Psychopharmacol, 11, pp.168~177 (2000)
22. Taylor D, "The Maudsley prescribing guidelines in psychiatry" (2012), Wiley-Blackwell
23. Pramyothin P, "Metabolic syndrome with the atypical antipsychotics", Curr Opin Endocrinol Diabetes Obes, 17, pp.460~466 (2010)
24. Stroup TS, "Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia", Am J Psychiatry, 173, pp.166~173 (2016)
25. Mitchell AJ, "Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis", Schizophr Bull, 39, pp.306~318 (2013)
26. Ahmed M, "Prevalence and associations of the metabolic syndrome among patients prescribed clozapine", Ir J Med Sci, 177, pp.205~210 (2008)
27. Softic R, "Metabolic syndrome in schizophrenia - who is more to blame: FGA polypharmacy or clozapine monotherapy?", Psychiatr Danub, 27, pp.378~384 (2015)
28. Zhang Y, "Metabolic syndrome in patients taking clozapine: prevalence and influence of catechol-O-methyltransferase genotype", Psychopharmacology (Berl), 231, pp.2211~2218 (2014)
29. Hyde N, "Prevalence of cardiovascular and metabolic events in patients prescribed clozapine: a retrospective observational, clinical cohort study", Curr Drug Saf, 10, pp.125~131 (2015)
30. Raedler TJ, "Cardiovascular aspects of antipsychotics", Curr Opin Psychiatry, 23, pp.574~581 (2010)
31. Henderson DC, "Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality:results of a 10-year naturalistic study", J Clin Psychiatry, 66, pp.1116~1121 (2005)
32. Koller E, "Clozapineassociated diabetes", Am J Med, 111, pp.716~723 (2001)
33. "The Electronic Medicines Compendium. Clozaril summary of product characteristics" (2013)[URL]
34. Nasrallah HA, "Factors in antipsychotic drug selection:tolerability considerations", CNS Spectr, 8(11 Suppl 2), pp.23~25 (2003)
35. Leonard P, "Prevalence of obesity, lipid and glucose abnormalities in outpatients prescribed clozapine", Ir Med J, 95, pp.119~120 (2002)
36. Wilson WH, "Clinical review of clozapine treatment in a state hospital", Hosp Community Psychiatry, 43, pp.700~703 (1992)
37. Freudenreich O, "Clozapine-induced electroencephalogram changes as a function of clozapine serum levels", Biol Psychiatry, 42, pp.132~137 (1997)
38. Günther W, "EEG alterations and seizures during treatment with clozapine. A retrospective study of 283 patients", Pharmacopsychiatry, 26, pp.69~74 (1993)
39. Welch J, "Clozapine-induced seizures and EEG changes", J Neuropsychiatry Clin Neurosci, 6, pp.250~256 (1994)
40. Atkinson JM, "Outcome following clozapine discontinuation: a retrospective analysis", J Clin Psychiatry, 68, pp.1027~1030 (2007)
41. Funderburg LG, "Seizure following addition of erythromycin to clozapine treatment", Am J Psychiatry, 151, pp.1840~1841 (1994)
42. Varma S, "Clozapinerelated EEG changes and seizures: dose and plasma-level relationships", Ther Adv Psychopharmacol, 1, pp.47~66 (2011)
43. Bailey L, "Factors predicting use of laxatives in outpatients stabilized on clozapine", Ther Adv Psychopharmacol, 5, pp.256~262 (2015)
44. Kusumi I, "Monitoring of side effects induced by psychotropic drugs", Seishin Shinkeigaku Zasshi, 116, pp.116~122 (2014)
45. Martin J, "British National Formulary (BNF)" (2013), BMJ Group
46. Meltzer HY, "Effect of clozapine on human serum prolactin levels", Am J Psychiatry, 136, pp.1550~1555 (1979)
47. Volavka J, "Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol", J Clin Psychiatry, 65, pp.57~61 (2004)
48. Stark A, "A review of the use of clozapine levels to guide treatment and determine cause of death", Aust N Z J Psychiatry, 46, pp.816~825 (2012)
49. Flanagan R, "Clozapine therapeutic drug monitoring: why it is important?", British J Clin Pharm, 3, pp.18~20 (2011)
50. Llorca PM, "Effectiveness of clozapine in neuroleptic-resistant schizophrenia:clinical response and plasma concentrations", J Psychiatry Neurosci, 27, pp.30~37 (2002)
51. Simpson GM, "Clozapine plasma levels and convulsions", Am J Psychiatry, 135, pp.99~100 (1978)
52. Cadeddu G, "Clozapine toxicity due to a multiple drug interaction: a case report", J Med Case Rep, 9, pp.77~ (2015)
53. Taylor D, "Pharmacokinetic interactions involving clozapine", Br J Psychiatry, 171, pp.109~112 (1997)
54. Spina E, "Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia", Int Clin Psychopharmacol, 13, pp.141~145 (1998)
55. Centorrino F, "Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors", Am J Psychiatry, 153, pp.820~822 (1996)
56. Lu ML, "Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances", J Clin Psychiatry, 65, pp.766~771 (2004)
57. Lu ML, "Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients", J Clin Psychiatry, 61, pp.594~599 (2000)
58. Légaré N, "Increasing the clozapine: norclozapine ratio with co-administration of fluvoxamine to enhance efficacy and minimize side effects of clozapine therapy", Med Hypotheses, 80, pp.689~691 (2013)
59. Olesen OV, "Fluvoxamine-clozapine drug interaction:inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism", J Clin Psychopharmacol, 20, pp.35~42 (2000)
60. Treves IA, "EEG abnormalities in clozapinetreated schizophrenic patients", Eur Neuropsychopharmacol, 6, pp.93~94 (1996)
61. Haring C, "EEG alterations in patients treated with clozapine in relation to plasma levels", Psychopharmacology (Berl), 114, pp.97~100 (1994)
62. Malow BA, "Spectrum of EEG abnormalities during clozapine treatment", Electroencephalogr Clin Neurophysiol, 91, pp.205~211 (1994)
63. Gross A, "Clozapineinduced QEEG changes correlate with clinical response in schizophrenic patients: a prospective, longitudinal study", Pharmacopsychiatry, 37, pp.119~122 (2004)
64. Khodayari-Rostamabad A, "A pilot study to determine whether machine learning methodologies using pre-treatment electroencephalography can predict the symptomatic response to clozapine therapy", Clin Neurophysiol, 121, pp.1998~2006 (2010)
65. "Efficacy of somatic treatments in treatment resistant schizophrenia" (2000)[URL]
66. Singh SP, "Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia:meta-analysis", Br J Psychiatry, 197, pp.174~179 (2010)

관련 논문AI추천